May 2023 Br J Cardiol 2023;30:69 doi:10.5837/bjc.2023.014
Derek L Connolly, Azfar Zaman, Nigel E Capps, Steve C Bain, Kevin Fernando
Introduction Statins are the gold-standard lipid-lowering therapy based on their efficacy in reducing serum low-density lipoprotein cholesterol (LDL-C) and general tolerability.1 While statins have an extensive body of evidence that have shown them to reduce the risk of cardiovascular (CV) events,2,3 there are concerns around side effects. An increase in cases of treatment-induced comorbidities, such as new-onset diabetes mellitus (NODM) has been observed.4-6 When combined with patient and media concerns, this has led to a reported 50% drop-out rate within 12 months.1 In response, other LDL-C lowering medications have been developed. Proprote
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits